Home » Newsletters » BioWorld Science

BioWorld Science

July 5, 2001

View Archived Issues

Pfizer succeeds in enhancing CNS penetration of a potent and selective NK1 antagonist

Forest licenses NMDA antagonist from Merz

AEterna's Neovastat demonstrates safety and dose-related activity in prostate cancer trial

TAU, Elan and AHP to codevelop immunological approaches to Alzheimer's disease

Genetronics and Chiron sign second agreement relating to electroporation

Bradykinin B2 antagonists with anticancer activity

Ertapenem: in vitro activity against anaerobic isolates from patients

Important Gram-positive and Gram-negative bacteria tested for susceptibility to BMS-284756

PSK evaluated in clinical trials as adjuvant immunochemotherapy in colorectal cancer

Peregrine's TNT treatment shows positive results in phase I/II trial

U.S. university researchers design potent and selective human MC4 receptor agonist

Pharmacological profile of KF-19418 suggests potential in human alopecia

Organon Teknika's diagnostic unit acquired by bioMerieux

Vernalis and Alcon enter glaucoma alliance

High-dose coenzyme Q10 proves safe and effective in migraine prevention

Patient enrollment complete in VALIANT trial of Diovan for long-term survival following MI

NewBiotics presents data supporting antibiotic that exploits the resistance enzyme

Dianon Systems to acquire UroCor

Schering AG creates new company

Human fibroblast growth factor gene and use in cirrhosis and cancer

Merck KGaA presents new modified EPO forms

Antibacterial and antiprotozoal erythromycin-based compounds

Novel compounds synthesized at Fujimoto useful for hyperlipidemia

Metalloprotease inhibitors with therapeutic potential discovered at Roche

Treatments for prostaglandin-mediated diseases in development at Merck Frosst

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 3, 2026